Is demyelination a primary feature of critical illness neuromyopathy (CIM) in critically ill patients?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 27, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Is There Demyelination in Critical Illness Myopathy (CIM)?

No, demyelination is not a primary feature of critical illness myopathy (CIM)—this condition is characterized by axonal injury and myopathic changes, not demyelination. 1, 2

Pathophysiological Characteristics of CIM

Critical illness polyneuromyopathy (CIPNM) is fundamentally an acute axonal sensory-motor polyneuropathy, not a demyelinating disorder. 3 The key pathological features include:

  • Axonal degeneration affecting peripheral nerves, which distinguishes this from demyelinating polyneuropathies like Guillain-Barré syndrome 1, 3
  • Myonecrosis and muscle fiber changes, including extensive type 2 fiber atrophy, disarray of sarcomere architecture, and selective loss of myosin 2
  • Preserved myelin sheaths in nerve conduction studies, with the primary abnormality being reduced compound motor action potential (CMAP) amplitudes rather than prolonged latencies 2

Electrophysiological Distinction from Demyelinating Disorders

The electrophysiological profile of CIM clearly differentiates it from demyelinating conditions:

  • Normal or near-normal nerve conduction latencies (6-8 milliseconds for phrenic nerve/diaphragm in adults), which would be prolonged in demyelinating polyneuropathies 1
  • Severely reduced CMAP amplitudes indicating axonal loss rather than demyelination 2
  • Phrenic nerve/diaphragm latencies are abnormally slow in demyelinating polyneuropathies like Guillain-Barré syndrome, but this is not the pattern seen in CIPNM 1

Clinical Implications

Understanding that CIM is an axonal/myopathic process rather than a demyelinating one has important clinical implications:

  • The prognosis differs significantly—axonal injury typically requires longer recovery periods with potential for incomplete recovery, whereas demyelinating disorders may show faster recovery once remyelination occurs 1, 2
  • Severe axonal critical care neuropathies result in prolonged periods of convalescence and incomplete recovery 1
  • Electrophysiological studies can distinguish between the axonal pattern of critical illness polyneuropathy and the myopathic patterns, both of which lack demyelination 2

Common Diagnostic Pitfall

A critical pitfall is confusing CIPNM with Guillain-Barré syndrome or other demyelinating polyneuropathies based solely on clinical weakness. 1 The key distinguishing features are:

  • Preserved sensory function in CIPNM versus sensory involvement in many demyelinating neuropathies 2
  • Context of critical illness with sepsis, prolonged mechanical ventilation, and exposure to neuromuscular blocking agents or corticosteroids 1
  • Electrophysiological findings showing axonal loss (reduced CMAP amplitudes) with normal conduction velocities, rather than the slowed conduction velocities characteristic of demyelination 1, 2

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Characteristic Features of Critical Illness Neuromyopathy

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

Critical illness polyneuromyopathy.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2012

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.